ESMO 2016
Interviews and expert commentary from ESMO 2016 — study authors and key opinion leaders discuss the findings and their clinical implications.
First-Line Pembrolizumab Boosts Survival in PD-L1-Positive Advanced Lung Cancer
Audio Journal of Oncology, January 2, 2017 COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to ini
Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib
COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the se
PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer
The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab e
Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit
COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced n
Vantictumab Combination Benefits Patients with Stage IV Pancreatic Cancer
Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh
Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer
COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical O